Bioheart
Sunrise
About Bioheart
Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases. Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart's goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart’s leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $19.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2014)
- Ticker: nasdaq:BHRT
- Website: bioheartinc.com
- Phone: 954-835-1500
Industries & Categories
Biotechnology, Developer Platform, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/bioheart-1048998 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.